尽管Apogee Therapeutics表现优于盈利，仍将评级下调至“卖出”，理由是预计亏损和市场波动。 Apogee Therapeutics downgraded to "Sell" despite beating earnings, citing projected losses and market volatility.

尽管季度每股亏损1.11美元，超出盈利预期，华尔街Zen将Apogee Therapeutics（APGE）评级从“持有”下调至“卖出”。 Apogee Therapeutics (APGE) has been downgraded to "Sell" from "Hold" by Wall Street Zen despite beating earnings estimates with a quarterly loss of $1.11 per share. 该公司开发用于治疗外皮皮炎和脑膜炎等发炎性疾病的生物生物学,预计本财政年度损失3.09美元。 The company, developing biologics for inflammatory diseases like atopic dermatitis and COPD, projects a $3.09 loss for the current fiscal year. 虽然分析家对其输油管(包括APG777和APG808)仍然持乐观态度,但市场情绪好坏参半,P/E比率为负,波动性很大。 While analysts remain optimistic about its pipeline—including APG777 and APG808—market sentiment is mixed, with a negative P/E ratio and high volatility. 股票交易额为76.09美元,市场上限为52亿美元,机构所有权占42.77%。 The stock trades at $76.09 with a market cap of $5.2 billion and 42.77% institutional ownership.